About Climb Bio

Climb Bio is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. Our pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy.